Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking naproxen alongside semaglutide is not automatically off-limits, but the combination carries a real gastrointestinal risk that your prescriber needs to know about before you reach for the packet. Semaglutide slows the stomach's emptying rate and can cause nausea and gastric discomfort on its own; naproxen, as a non-steroidal anti-inflammatory drug (NSAID), irritates the stomach lining directly. Together, those two mechanisms can compound. Neither the NHS semaglutide page nor the Wegovy SmPC lists naproxen as a banned combination, but clinical guidance consistently recommends caution with NSAIDs during GLP-1 treatment, particularly at higher doses or with regular use. These are prescription-only medicines, and only a prescriber who knows your full medication list can judge whether the combination is appropriate for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is probably the most common misconception our prescribers hear about NSAIDs on semaglutide. Because naproxen is available over the counter for around £3 a packet, people reasonably assume it sits in a different category from prescription medicines and doesn't need to be declared. It does.
Naproxen works by inhibiting COX-1 and COX-2 enzymes. The COX-1 side of that action reduces the protective prostaglandins that line the stomach wall. Even a short course can cause gastric irritation, micro-erosions or, in susceptible people, a more serious ulcer, particularly on an empty or near-empty stomach. Semaglutide, separately, slows the rate at which the stomach empties its contents into the small intestine. That means naproxen may sit in contact with the gastric lining for longer than it ordinarily would, which amplifies the irritant effect. It also means absorption timing changes, though the clinical significance of that varies between individuals.
The result isn't a dramatic drug–drug interaction in the pharmacokinetic textbook sense. It's a compounding of two different gastric insults. For someone already managing nausea at the start of treatment or after a dose increase, adding naproxen can tip manageable discomfort into something that genuinely needs assessment. That's the thing worth understanding, not a label warning in small print.
If you regularly take naproxen for a chronic condition such as arthritis or back pain, that conversation with your prescriber about naproxen and Wegovy is not optional. Short-term use for a headache or a pulled muscle is a different picture, but still worth flagging.
The NHS guidance on semaglutide lists the common side effects as nausea, vomiting, diarrhoea, constipation, stomach pain and indigestion. Those symptoms are most pronounced when treatment begins or after a dose step up. Naproxen's gastric side effects follow a similar upper-GI pattern: nausea, heartburn, stomach cramping and, with heavier use, the risk of bleeding.
In practice, the concern is additive rather than synergistic, you're not facing a sudden dramatic reaction, but a raised baseline risk of upper GI symptoms that can be harder to manage and slower to settle. People who already have a history of peptic ulcer disease, gastro-oesophageal reflux or who take aspirin alongside everything else are at higher risk still.
A proton pump inhibitor (PPI) such as omeprazole is sometimes prescribed alongside an NSAID to protect the stomach lining; if your GP has already set that up, tell your semaglutide prescriber too, because the PPI itself is another oral medicine whose absorption timing may shift slightly with delayed gastric emptying.
If you develop severe or persistent stomach pain while taking both (particularly pain that spreads toward the back) seek medical help promptly. That symptom pattern can indicate pancreatitis, which the MHRA flagged in its January 2026 Drug Safety Update on GLP-1 medicines as an infrequent but serious risk. You can report any suspected side effects at the MHRA's Yellow Card scheme.
Paracetamol is generally the first-choice alternative for pain during semaglutide treatment. It does not irritate the stomach lining via the COX pathway and has no meaningful interaction with semaglutide's gastric-emptying mechanism at standard doses. For most mild-to-moderate pain, it's the safer starting point.
Ibuprofen carries the same class of concern as naproxen, both are NSAIDs, both reduce prostaglandin protection of the stomach lining. A fuller look at that specific comparison is covered on our ibuprofen and semaglutide page. Topical NSAIDs (gels applied directly to the skin) are absorbed in much smaller amounts systemically and present a lower gastric risk, making them a reasonable option for localised musculoskeletal pain, though again, tell your prescriber.
Codeine-based preparations have their own considerations and should only be used under clinical guidance. The broader point is that pain management during semaglutide treatment is not simply a matter of grabbing whatever is in the bathroom cabinet. Semaglutide changes the gastric environment. It's a detail that shapes which medicines are the right choice, not just a background footnote.
If you're unsure about a specific medicine you need to take, the nume FAQs cover common questions, or you can contact our team directly.
Before starting semaglutide, you'll complete a clinical consultation. Listing every medicine you take (prescribed, over-the-counter and any supplements) is part of that process, and questions such as whether you can take berberine and semaglutide together are exactly the kind of thing worth raising at that stage. At nume, a named GPhC-registered prescriber reads your answers and reviews your history personally; if naproxen appears regularly, or if you've been using it for a chronic condition, that's a relevant clinical fact.
The same applies at every repeat. If your pain management changes between orders (a new prescription for an NSAID from your GP, for example) tell the prescriber at your next review. The eligibility picture for semaglutide is about the whole clinical context, not just a BMI figure checked once and filed away. Regular NSAID use might mean a prescriber recommends a different pain-relief approach, or decides a PPI is worth adding, or simply monitors more closely. None of those options are available if the information isn't shared.
If you're already on semaglutide and you've been taking naproxen occasionally without mentioning it, the practical step is to raise it at your next contact. That's not a reason to stop your treatment unilaterally, stopping abruptly has its own implications. Speak to the prescribing team first.
Semaglutide is licensed in the UK as Wegovy for weight management, and the full eligibility criteria, including BMI thresholds, are covered on our BMI for semaglutide page. If you're ready to discuss your full medication picture with a prescriber, you can check your eligibility through a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.